Holen Sie sich die Stockscreener-App
5.31
1.63%
0.08
Schlusskurs vom Vortag:
$5.23
Offen:
$5.23
24-Stunden-Volumen:
1.44M
Relative Volume:
1.03
Marktkapitalisierung:
$350.62M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
-4.2823
EPS:
-1.24
Netto-Cashflow:
$10.68M
1W Leistung:
+5.88%
1M Leistung:
+14.06%
6M Leistung:
+195.28%
1J Leistung:
-57.95%
1-Tages-Spanne:
$4.98
$5.416
1-Wochen-Bereich:
$4.5701
$5.88
52-Wochen-Spanne:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AMLX | 5.31 | 350.62M | 380.79M | 49.27M | 10.68M | -1.24 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.25 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Baird R W - MarketBeat
Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance
Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks
Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharma - GuruFocus.com
Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN
BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia
BofA upgrades Amylyx stock to Buy rating - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
October 2024's US Penny Stocks Poised For Growth - Simply Wall St
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN
Amylyx shares reiterate Buy rating on trial data - Investing.com
Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance
Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com
Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa
Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India
Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - StockTitan
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):